zervimesine
Generic: CT1812·Code: CT1812
zervimesine: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| COGNITION THERAPEUTICS INC (CGTX) | Phase 2 |
FDA Decisions
FDA_MeetingCompleted Type C meeting with the U.S. FDA for zervimesine in dementia with Lewy bodies; filing references a press release (Exhibit 99.1) without further details.(CGTX)
Frequently asked questions
Who is developing zervimesine?
zervimesine is being developed by COGNITION THERAPEUTICS INC.
What is zervimesine's latest FDA decision?
The most recent tracked FDA decision for zervimesine is FDA_Meeting for Completed Type C meeting with the U.S. FDA for zervimesine in dementia with Lewy bodies; filing references a press release (Exhibit 99.1) without further details..
Get deeper analysis on zervimesine
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis